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628Right Heart Score for Predicting Outcome
in Idiopathic, Familial, or Drug- and Toxin-
Associated Pulmonary Arterial HypertensionABSTRACTOBJECTIVES This study sought to determine whether a simple score combining indexes of right ventricular(RV) function and right atrial (RA) size would offer good discrimination of outcome in patients with pulmonary arterial
hypertension (PAH).BACKGROUND Identifying a simple score of outcome could simplify risk stratiﬁcation of patients with PAHand potentially lead to improved tailored monitoring or therapy.METHODS We recruited patients from both Stanford University (derivation cohort) and VU University MedicalCenter (validation cohort). The composite endpoint for the study was death or lung transplantation. A Cox proportional
hazard with bootstrap CI adjustment model was used to determine independent correlates of death or transplantation.
A predictive score was developed using the beta coefﬁcients of the multivariable models.RESULTS For the derivation cohort (n ¼ 95), the majority of patients were female (79%), average age was 43
 11 years, mean pulmonary arterial pressure was 54  14 mm Hg, and pulmonary vascular resistance index was 25  12
Wood units  m2. Over an average follow-up of 5 years, the composite endpoint occurred in 34 patients, including 26
deaths and 8 patients requiring lung transplant. On multivariable analysis, RV systolic dysfunction grade (hazard ratio
[HR]: 3.4 per grade; 95% conﬁdence interval [CI]: 2.0 to 7.8; p < 0.001), severe RA enlargement (HR: 3.0; 95% CI: 1.3 to
8.1; p ¼ 0.009), and systemic blood pressure <110 mm Hg (HR: 3.3; 95% CI: 1.5 to 9.4; p < 0.001) were independently
associated with outcome. A right heart (RH) score constructed on the basis of these 3 parameters compared favorably
with the National Institutes of Health survival equation (0.88; 95% CI: 0.79 to 0.94 vs. 0.60; 95% CI: 0.49 to 0.71;
p < 0.001) but was not statistically different than the REVEAL (Registry to Evaluate Early and Long-Term PAH Disease
Management) score c-statistic of 0.80 (95% CI: 0.69 to 0.88) with p ¼ 0.097. In the validation cohort (n ¼ 87), the RH
score remained the strongest independent correlate of outcome.CONCLUSIONS In patients with prevalent PAH, a simple RH score may offer good discrimination of long-termoutcome. (J Am Coll Cardiol Img 2015;8:627–38) © 2015 by the American College of Cardiology Foundation.SEE PAGE 639
P ulmonary arterial hypertension (PAH) is arare condition caused by the progressive nar-rowing of the small pulmonary arteries, lead-
ing to increased pulmonary vascular resistance and
right-sided heart failure (1). Despite advances in
therapy, the mortality remains high, approaching
30% to 50% at 5 years in symptomatic patients
(1,2). In recent years, right ventricular (RV) function
has emerged as one of the strongest predictors of
outcome in PAH (3). Hemodynamic studies have
highlighted the prognostic importance of elevated
right atrial (RA) pressure and decreased cardiac
output, whereas imaging studies have highlighted
the importance of RV remodeling and systolic func-
tion (2,4–6). Moreover, recent scores, such as the
REVEAL (Registry to Evaluate Early and Long-
Term PAH Disease Management) score, haveintegrated several of the clinical and functional
parameters (2).To date, only a few studies have investigated
whether RA size or function has incremental value to
RV function in predicting outcome in PAH. The
importance of RA size in PAH was ﬁrst suggested by
Bustamente-Labarta et al. (7) in their series of 25 pa-
tients. In a larger study in patients with PAH (n ¼ 81),
Raymond et al. (8) found that there was a trend for an
independent association between RA area index (p ¼
0.106) and the composite endpoint of death or
transplantation. To our knowledge, no study has of
yet also investigated the prognostic value of RA
function measured by active and passive emptying
fractions (RAEF) in PAH.
AB BR E V I A T I O N S
AND ACRONYM S
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
PAH = pulmonary arterial
hypertension
PVRI = pulmonary vascular
resistance index
RAEF = right atrial emptying
fractions
RAP = right atrial pressure
RVEDA = right ventricular
end-diastolic area
RVEF = right ventricular
ejection fraction
RVESA = right ventricular
end-systolic area
RVFAC = right ventricular
fractional area change
RVGLS = right ventricular
global longitudinal strain
RVMPI = right ventricular
myocardial performance index
SBP = systolic blood pressure
TAPSE = tricuspid annular
systolic excursion
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629For our study, we ﬁrst hypothesized that measures
of RA size or function would be independently asso-
ciated with event-free survival in PAH. We further
hypothesized that a simple score combining quanti-
tative measures of right heart size or function would
provide good discrimination of outcome in PAH.
METHODS
STUDY DESIGN. Our study included a derivation
cohort at Stanford University, followed by a valida-
tion cohort at the VU Medical Center. After ethics
committee approval, consecutive adult patients fol-
lowed at Stanford University between January 11,
1999 and January 12, 2009 with a conﬁrmed diagnosis
of idiopathic or drug and toxin PAH were considered
for inclusion in the study. The diagnosis of PAH was
on the basis of the standard deﬁnition of mean pul-
monary arterial pressure $25 mm Hg and pulmonary
artery wedge pressure #15 mm Hg (9). We excluded
patients for whom an echocardiogram was not avail-
able and patients with evidence of atrial ﬁbrillation at
baseline, left heart failure, and signiﬁcant paren-
chymal lung disease. Patients recruited at the VU
Medical Center had a diagnosis of idiopathic or fa-
milial PAH and underwent cardiac magnetic reso-
nance (CMR) as part of a prospective study to evaluate
the role of CMR in the management of PAH, for which
medical ethical consent approval was obtained.
The composite endpoint of the study was
death or lung transplantation. Death was veriﬁed
through the national Social Security Death Index and
transplantation through chart review. Data collec-
tion included demographics, 6-min walking dis-
tance (6MWD), estimated glomerular ﬁltration rate,
N-terminal pro–B-type natriuretic peptide (NT-
proBNP) levels, diffusion capacity of carbon monox-
ide, and hemodynamics. Renal function was
estimated using the modiﬁed diet and renal equation
(10). For purposes of standardization, data were
collected on the ﬁrst outpatient visit after stabiliza-
tion on disease-modifying medications (prostanoids,
endothelin receptor blockers, or phosphodiesterase
inhibitors). We chose this time point for 2 reasons.
First, this time point corresponded to the same day
patients completed echocardiography, 6MWD, and
laboratory testing (metabolic panel and NT-proBNP).
In addition, the baseline right heart catheterization
was often obtained within a 3- to 6-month time frame
of this visit.
ECHOCARDIOGRAPHY. Digitized echocardiographic
studies were analyzed by the Stanford Cardiovascular
Institute biomarker and phenotypic core laboratory
in accordance with published guidelines of theAmerican Society of Echocardiography (ASE)
(11). All measures were averaged over 3
cycles, and RV or RA size measures were
indexed to body surface area. RV end-
diastolic and end-systolic areas, as well as
RA size, were measured from the apical
4-chamber view (Figure 1). RV function was
quantiﬁed using right ventricular fractional
area change (RVFAC), tricuspid annular sys-
tolic excursion (TAPSE), and right ventricular
myocardial performance index (RVMPI), as
previously described (11–13). RA size was
measured at end-systole (RAmax), pre-atrial
contraction (RApre-A), and end-diastole
(RAmin) (Figure 2), and total, passive, and
active RAEF were calculated as follows:
RAEFtotal ¼ (RAmax  RAmin)/RAmax;
RAEFpassive ¼ (RAmax  RApre-A)/RAmax; and
RAEFactive ¼ (RA pre-A size  RA min size)/
RApre-A.
REFERENCE VALUES FOR RIGHT HEART
REMODELING AND FUNCTION. RV systolic
dysfunction was classiﬁed as mild, moderate,
or severe if RVFAC was 25% to 35%, 18% to
24%, or #17%, respectively (11). For indexed
values of RA size and function, because no values are
referenced in the ASE guidelines, we used 95% of the
upper limit of 95 prospectively recruited age- and
sex-matched healthy controls on the basis of
a 50-point questionnaire. Dimensions were catego-
rized using similar thresholds as the left atrial
volumes: <18% from reference value increase for
mild increase and >40% increase for severe increase.
For indexed RA area and right ventricular end-
diastolic area (RVEDA), the upper limit of normal
was 11 cm2/m2 and for indexed right ventricular
end-systolic area (RVESA), the upper limit was
7.5 cm2/m2.
CMR PROTOCOL IN THE VALIDATION COHORT. CMR
was performed on a 1.5-T Sonato scanner (Siemens
Medical Solutions, Erlangen, Germany), equipped
with a 6-element phased-array receiver coil. Short-
axis images from base to apex of the ventricles were
obtained with a typical slice thickness of 5 mm, and
an interslice gap of 5 mm was used for estimation of
ventricular volumes using the Simpson method, as
previously described (14). The thresholds chosen for
the CMR categorical classiﬁcation were pre-deﬁned at
the beginning of the study. We chose the threshold of
35% for moderate RVEF dysfunction similar to the
previously established cutoff in the study of van de
veerdonk et al. (14). In addition, on the basis of a prior
study from our group, we found that RVFAC of 25%
FIGURE 1 Representative Measures of Right Heart Size and Functional Parameters
(A) Measures of right ventricular end-diastolic area (RVEDA). (B) Measures of right ventricular end-systolic area (RVESA) and 2-dimensional
tricuspid annular systolic excursion (TAPSE). (C)Measures of tricuspid regurgitation (TR) duration. (D)Measures of RV ejection time. RA ¼ right
atrial; RVET ¼ right ventricular ejection time; RVFAC ¼ right ventricular fractional area change; RVMPI ¼ right ventricular myocardial per-
formance index.
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630corresponded best to an RVEF of 35% (15). We used
the same threshold for RA area for the echocardio-
graphic and CMR studies.
STATISTICAL ANALYSIS. Continuous data are pre-
sented as mean  SD if the Kolmogorov-Smirnov test
showed a normal distribution; otherwise, data are
presented as median  interquartile range (IQR).
Categorical variables are expressed as frequency and
percentage. Comparisons between groups were per-
formed using 2-sided Student t tests with adjustment
for unequal variance as needed. For non-normally
distributed variables such as NT-pro-BNP level,
transformation to the common logarithm was per-
formed before analysis. Linear regression analysis
was used to determine independent associations bet-
ween hemodynamic and structural or functional right
heart parameters. The association between clinicaland echocardiographic parameters and outcome was
analyzed using Cox proportional hazards models. The
assumption of proportional hazards was assessed by
plotting the scaled Schoenfeld residuals for each in-
dependent variable against time; these correlations
were found to be nonsigniﬁcant for all variables
included in the multivariable model. We used hierar-
chical modeling to determine factors independently
associated with outcome and chose to include at
maximum 1 covariate per 10 events to minimize
overﬁtting of the model. We avoided including in the
model variables that were collinearly related to each
other. We used bootstrapping with 5,000 iterations to
estimate hazard ratios and bias-corrected 95% conﬁ-
dence interval (CI) for the multivariable models. For
building the predictive score, the smallest absolute
beta coefﬁcient was assigned a value of 0 and values
for subsequent variables were assigned on the basis of
FIGURE 2 Atrial Size and Emptying Fractions
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emptying fractions; Vmax ¼ maximal volume; Vmin ¼ minimal volume; VpreA ¼ pre-atrial
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631multiples of their respective beta coefﬁcients to the
nearest 0.5 approximation for categories with signiﬁ-
cantly different beta coefﬁcients (16). The survival
c-statistic was calculated to show the discriminatory
ability of the models and was used to compare the
predictive score with the validated REVEAL score and
National Institutes of Health (NIH) survival equation.
Intraobserver variability was assessed using the
average difference in absolute measurement and the
intraclass correlation coefﬁcient (ICC). Statistical
analysis was done using PASW statistical program
(version 18.0, SPSS Inc., Chicago, Illinois).
RESULTS
STUDY POPULATION. Of 128 patients with idiopathic
and drug- and toxin-associated PAH who were seen
during the study period, 106 were enrolled in the
prospective registry. Eleven patients were excluded
from the study for the following reasons: unavailable
echocardiogram (n ¼ 2), atrial ﬁbrillation (n ¼ 1), lost
to follow-up (n ¼ 5), left heart failure (n ¼ 2), and
restrictive lung disease (n ¼ 1). Table 1 summarizes
the characteristics of the study population. The
average follow-up time for our study was 5.0  2.4
years. The mean pulmonary arterial pressure was
54  14 mm Hg, and the pulmonary vascular resis-
tance index (PVRI) score was 25  12 Wood units m2.
Forty-ﬁve percent of patients (n ¼ 43) were on pros-
tanoid therapy, and 19% of patients (n ¼ 18) were on
combination therapy.
Figure 3 summarizes the relationship between RA
size, RAEF, and RV function as assessed by RVFAC.
Compared with healthy controls, patients with PAH
had a greater degree of RA and RV enlargement
and lower RAEF. In general, RA enlargement and
impaired active RAEF were more common among
patients with severe RV dysfunction (Figures 3B
and 3D).
RELATIONSHIP BETWEEN METRICS OF RIGHT HEART
FUNCTION AND HEMODYNAMICS. The different para-
meters of right heart size and function are not inde-
pendent of each other; their inter-relationship is
important to consider before outcome models are
built. As expected, there was also strong collinearity
between parameters of RV function (R2 ¼ 0.61 be-
tween RVFAC and TAPSE [p < 0.001] and R2 ¼ 0.51
between RVFAC and RVMPI [p < 0.001]), as well as
between RVEDA and RA area (R2 ¼ 0.51; p < 0.001).
Table 2 summarizes factors independently associated
with RVFAC, RA area index, active and passive RAEF,
and log NT-proBNP levels. We favored including in
the model factors that were not only correlates but
also potential determinants. As covariates, factorsconsidered included demographic factors (age and
sex), load parameters (PVRI and right atrial pressure
[RAP]), functional indexes (tricuspid regurgitation
and TAPSE), or renal function for NT-proBNP. Among
other associations, we found that pericardial effu-
sion, which was present in 17 patients, was strongly
related to both RAP and RA size (chi-square ¼ 22;
p ¼ 0.01). Systolic blood pressure (SBP) was signiﬁ-
cantly correlated with cardiac output, as well as the
use of intravenous prostanoids (R2 ¼ 0.28; p < 0.011;
r ¼ 0.40 with cardiac output and r ¼ 0.28 with
prostanoids).
OUTCOME ANALYSIS IN THE DERIVATION COHORT. The
composite endpoint occurred in 34 patients (36%),
including 26 deaths and 8 lung transplants. Event-free
survival at 1, 3, and 5 years was 95%, 89%, and
81%, respectively. The predicted NIH survival equa-
tion 1-, 3-, and 5-year survival estimates were 66%,
44%, and 33%, respectively, and the revised NIH
prediction scores were 91%, 71%, and 63% (17).
Several parameters of right heart structure and
function were strongly related to outcome on uni-
variate analysis (Table 3). The strongest relationships
were found with RVEDA index, RVESA index, RVFAC,
TAPSE, RA size, active RAEF, and log NT-proBNP
levels. In addition, New York Heart Association
(NYHA) functional class, resting SBP, kidney func-
tion, low cardiac index on right heart catheterization,
and PVRI were associated with outcome. Figure 4
presents the c-statistic of the RV and RA parameters,
as well as their Kaplan-Meier survival curves from
RVFAC and RA index categories. With the area-length
TABLE 1 Patient Characteristics for the Derivation Cohort (N ¼ 95)
Age, yrs 43  11
Women 75 (79)
White 84 (88)
Etiology of PAH
Idiopathic or familial 44 (46)
Drugs and toxin (history of use) 51 (55)
Body mass index, kg/m2 30  6
Right heart catheterization
HR, beats/min 82  14
SBP, mm Hg 120  17
RAP, mm Hg 10  6
MPAP, mm Hg 54  14
PCWP, mm Hg 10  4
CI, l/min/m2 2.0  0.6
PVRI, Wood units  m2 25  12
6-min walking distance, m 432  117
DLCO, % 75  23
Comorbid conditions
CKD (eGFR <60 ml/min/1.73 m2) 22 (23)
Hyponatremia (<136 mEq/l) 9 (9.5)
Diabetes mellitus 3 (3)
Systemic hypertension 4 (4)
Medication
Diuretic 48 (51)
Prostanoid therapy 43 (45)
Phosphodiesterase inhibitor 31 (33)
Endothelin receptor blocker 39 (41)
Warfarin 59 (63)
Values are mean  SD or n (%).
CI ¼ cardiac index; CKD ¼ chronic kidney disease; DLCO ¼ diffusion of carbon
monoxide; eGFR ¼ estimated glomerular ﬁltration rate; HR ¼ heart rate, MPAP ¼
mean pulmonary arterial pressure; PAH ¼ pulmonary arterial hypertension;
PCWP ¼ pulmonary capillary wedge pressure; PVRI ¼ pulmonary vascular resis-
tance index; RAP ¼ right atrial pressure; SBP ¼ systolic blood pressure.
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632method, volumetric measures of RA size or RAEF
were not associated with signiﬁcantly different
c-statistics (p ¼ 0.79 and p ¼ 0.87, respectively).
To minimize overﬁtting the multivariable Cox
proportional hazards model, we only included 4 var-
iables in the initial analysis (i.e., RVFAC, RA index,
resting SBP, and NYHA functional class III and IV vs. I
and II). The choice of variables was based on the
following rationale: 1) RVFAC was more strongly
associated with outcome than other RV functional
parameters and was not collinearly related to RA size
in contrast to RVEDA or RVESA; 2) RA size was more
reproducible than active RAEF in our study popula-
tion; 3) SBP was not collinearly related to RVFAC—in
contrast, there was a moderate relationship between
RV systolic pressure or relative RV systolic pressure
and RVFAC (r ¼ 0.45; p < 0.001 and r ¼ 0.48;
p < 0.001); and 4) NYHA functional class was related
to outcome in many previous studies. On multivari-
able analysis, RVFAC, RA size, and SBP were strongly
and independently associated with outcome, asshown in Table 4 (both in continuous and categorical
analyses). In the subgroup of patients for whom NT-
proBNP level was available (n ¼ 79), NT-proBNP
level was not retained in the multivariable model.
RIGHT HEART SCORE AND OTHER VALIDATED
SCORES. A right heart score was built on the basis of
the beta coefﬁcients of the multivariable model,
assigning a baseline value of 1 and additional points
for each category of risk (Table 5). The right heart
score had a c-statistic of 0.88 (95% CI: 0.79 to 0.94),
the REVEAL score had a c-statistic of 0.80 (95% CI:
0.69 to 0.88), and the NIH survival equation had a
c-statistic of 0.60 (95% CI: 0.49 to 0.71). With the
DeLong method, both the right heart score and the
REVEAL score had signiﬁcantly higher c-statistics
than the NIH survival equation (p < 0.001 and p ¼
0.013, respectively). There was no statistical differ-
ence between the right heart score and the REVEAL
score in the cohort (p ¼ 0.097). Figure 5 illustrates the
Kaplan-Meier survival curves associated with the
right heart score, as well as its relationship with other
scores.
VALIDATION COHORT. The validation cohort
included 87 patients with idiopathic or familial PAH
followed at VU Medical Center between 2001 and
2012. The average age was 47.8  16.0 years, the
majority of patients were female (75%), baseline PVR
was 11.2  5 Wood units, and baseline 6MWD was
407  127 m. All patients were on disease-modifying
therapy, the average time between CMR and diag-
nosis was 1.5  1.5 years, and the average follow-up
time was 4.2  3.2 years. The composite endpoint
occurred in 29 patients, including 23 deaths and
6 lung transplants. On univariate analysis, the stron-
gest correlates of outcome included right ventricular
ejection fraction (RVEF) (chi-square ¼ 12; p < 0.001),
RA index (chi-square ¼ 11; p < 0.001), RV end-systolic
volume index (chi-square ¼ 9; p < 0.001), right heart
score (chi-square ¼ 14; p < 0.001), and more weakly
6MWD (chi-square ¼ 5; p ¼ 0.03). On multivariable
analysis, right heart score (hazard ratio [HR]: 1.9 per
grade; 95% CI: 1.4 to 2.6) and age (HR: 1.3 per grade;
95% CI: 0.98 to 1.69) were the only 2 variables inde-
pendently associated with outcome, with chi-
square ¼ 19 (p < 0.001). The c-statistic for the right
heart score in the validation cohort (0.76; IQR: 0.66 to
0.84) was signiﬁcantly different from the c-statistic
for the NIH survival equation (0.59; IQR: 0.48 to
0.70; p ¼ 0.030). Because NT-proBNP levels and the
percentage-predicted diffusion capacity of carbon
monoxide were not systematically available, the
derived REVEAL score could not be calculated in the
majority of patients at the time of follow-up.
FIGURE 3 Ventricular and Atrial Remodeling and Function in the Study Population
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(A) Box-and-whisker plot of indexed RA and RV areas of patients with pulmonary arterial hypertension (PAH) and healthy controls. (B)
Box-and-whisker plot of indexed RA area according to the pre-deﬁned categories of right ventricular dysfunction (RVD). (C) Box-and-whisker
plot of total, active, and passive RAEF of patients with PAH and healthy controls. (D) Bar graph with 95% conﬁdence interval for mean value
for active RAEF, stratiﬁed according to the pre-deﬁned categories of RA size. In the box-and-whisker plots, the central box represents the
values from the lower to upper quartile (25th to 75th percentile); the middle line represents the median; and the line extends from the
minimum to the maximum value, excluding outlier values. RAE ¼ right atrial enlargement; RVF ¼ right ventricular function; other abbreviations
as in Figures 1 and 2.
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633INTERVARIABILITY OF ECHOCARDIOGRAPHIC
MEASURES. For RVFAC, the average difference in
absolute measurement was 2.1  1.6%, with an ICC of
0.84; for TAPSE, the average difference in absoluteTABLE 2 Potential Determinants of RV and RA Indexes (Multivariabl
RVFAC RAI
R2 0.32 0.61
Correlates PVRI (r ¼ 0.44)
Male (r ¼ 0.30)
RAP (r ¼ 0.44)
TR (r ¼ 0.45)
R
T
M
The multivariate models presented are all p < 0.001. PVRI is based on the most recent
NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; RAEF ¼ right atrial emptyin
change; TAPSE ¼ tricuspid annular systolic excursion; TR ¼ tricuspid regurgitation; othemeasurement was 0.1  0.1 cm, with an ICC of 0.93;
and for RVMPI, the average difference in absolute
measurement was 0.09  0.11, with an ICC of 0.85.
The ICCs for maximal, minimal, and pre-atrial systolee Regression Models)
RAEFactive RAEFpassive Log NT-proBNP
0.41 0.27 0.59
AP (r ¼ 0.27)
APSE (r ¼ 0.33)
ale (r ¼ 0.27)
Age (r ¼ 0.35)
TAPSE (r ¼ 0.47)
RVFAC (r ¼0.48)
RAI (r ¼ 0.40)
eGFR (r ¼ 0.31)
Male (r ¼ 0.24)
right heart catheterization. r corresponds to partial correlation coefﬁcients.
g fractions; RAI ¼ right atrial area index; RVFAC ¼ right ventricular fractional area
r abbreviations as in Table 1.
TABLE 3 Univariable Analysis of Factors Associated With the Composite Endpoint
Hazard Ratio 95% CI p Value
Clinical
Age, per 10 yrs 0.75 0.54–1.03 0.082
Male 1.90 0.90–4.03 0.094
DT vs. idiopathic 0.94 0.47–1.85 0.84
NYHA functional class, III and IV vs. I and II 2.67 1.34–5.32 0.005*
Walking distance, per 100 m 0.73 0.55–0.96 0.026*
SBP, per 10 mm Hg 0.73 0.58–0.92 0.009*
HR, per 10 beats/min 1.17 0.89–1.54 0.26
DLCO, per 10% 0.97 0.88–1.09 0.61
Comorbidities
CKD 2.18 1.07–4.46 0.033*
Hyponatremia 1.80 0.69–4.68 0.23
Log NT-proBNP 4.81 2.13–10.86 <0.001*
Echocardiography parameters
Right ventricular
RVEDAI, per 3 cm2/m2 1.60 1.29–2.04 <0.001*
RVESAI, per 3 cm2/m2 1.82 1.49–2.22 <0.001*
RVFAC, per 5% 0.52 0.41–0.67 <0.001*
TAPSE, per 0.3 cm 0.61 0.46–0.82 0.001*
RVMPI, per 0.3 U 2.06 1.16–3.69 0.015*
Right atrial
RAI, per 5 cm2/m2 1.81 1.44–2.28 <0.001*
RAEF active, per 5% 0.69 0.57–0.83 <0.001*
RAEF passive, per 5% 1.27 1.02–1.58 0.029
Septal curvature
Diastolic EI, per 0.5 U 1.84 1.19–2.87 0.007*
Systolic EI, per 0.5 U 1.33 1.11–1.57 0.001*
Tricuspid regurgitation 1.95 1.30–2.90 0.002*
Hemodynamic
RAP, per 5 mm Hg 2.12 1.51–3.01 <0.001*
RVSP, per 10 mm Hg 1.14 0.91–1.43 0.25
RVSP/SBP, per 0.25 2.77 1.61–4.75 <0.001*
SVI, per 5 ml/m2 0.82 0.70–0.97 0.019
Left ventricular
LVID, per 0.5 cm 0.79 0.54–0.99 0.049*
LVEF, per 5% 0.72 0.60–0.88 0.001*
Right heart catheterization
Cardiac index <1.8 l/min/m2 2.22 1.09–4.50 0.025
PVRI, per 10 Wood units  m2 1.41 1.02–1.96 0.039
*Statistically signiﬁcant.
DT ¼ drug and toxin; EI ¼ eccentricity index; LVID ¼ left ventricular internal dimension; LVEF ¼ left ventricular
ejection fraction; NYHA ¼ New York Heart Association; RVEDAI ¼ right ventricular end-diastolic area index;
RVESAI ¼ right ventricular end-systolic area index; RVMPI ¼ right ventricular myocardial performance index;
RVSP ¼ right ventricular systolic pressure; SVI ¼ stroke volume index; other abbreviations as in Tables 1 and 2.
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634RA volumes were 0.95, 0.97, and 0.87, respectively.
The ICC was 0.89 for total RAEF, 0.72 for active RAEF,
and 0.84 for passive RAEF.
DISCUSSION
Our study is the ﬁrst to demonstrate that a simple
score combining measures of RV systolic function,
RA size, and SBP offered a good discrimination of
outcome in patients with established PAH.Consistent with other studies, the results of our study
highlighted that the quantitative metrics of right
heart remodeling or function may simplify the risk
stratiﬁcation of patients with PAH (3,18).
The REVEAL score and the NIH survival equation
represent the 2 most validated survival scores in PAH
(2,4). The NIH registry score relies on hemodynamic
parameters, whereas the REVEAL registry score in-
corporates clinical, functional, and imaging parame-
ters. Although our sample size was small, conﬁdence
in our results is provided by the fact that the right
heart score correlated well with established outcome
scores, the ﬁndings were validated in an independent
cohort, and the results were consistent using dif-
ferent imaging modalities. In a recent publication, in
a large series of patients with PAH, Fine et al. (18)
showed that RV global longitudinal strain (RVGLS),
log NT-proBNP levels, and NYHA functional class
were independent correlates of clinical deterioration
in patients with PAH. Consistent with the study of
Fine et al. (18), our study also highlighted the
importance of right heart function. In contrast, NYHA
functional class and log NT-proBNP levels did not
emerge as independent correlates of outcome due to
their strong relationship with RV function and RA
size; alternatively, our study may have been under-
powered to assess their incremental value. In the
REVEAL registry score, qualitative assessment of RV
function was considered but did not emerge in the
multivariate model; one can theorize, although not
yet proven, that this may reﬂect the interlaboratory
variability in assessing RV function and the multiple
grades of dysfunction considered (5 classes).
With echocardiography, different metrics of RV
systolic function have been considered, including
RVFAC, TAPSE, RVMPI, and more recently RVGLS
(3,12,13,18). In our study, RVFAC emerged as a stronger
correlate of outcome than either TAPSE or RVMPI. In a
recent study, we showed that RVFAC was more closely
related to RVEF than TAPSE (19).Moreover, we showed
that an RVFAC of 25% corresponded best to an RVEF of
35%, a commonly chosen threshold for moderate RV
dysfunction in CMR imaging studies of patients with
PAH (14,15). In comparison to RVFAC, TAPSE has the
advantage of reproducibility but does not take into
account the radial component of RV contraction (20).
Although RVMPI combines information of both sys-
tolic and diastolic function, in different studies it has
not appeared to carry stronger prognostic value than
RVFAC, TAPSE, or RVGLS (18,21). Although not yet
proven, this may be in part due to pseudonormaliza-
tion of RVMPI values, which can occur in patients with
severe dysfunction. As shown in the recent study of
Fine et al. (18), RVGLS emerged as the bestmetric of RV
FIGURE 4 C-statistics and Kaplan-Meier Curves for Selected Parameters of RV and RA Function
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(A) C-statistic between indexes of RV function. (B) Five-year Kaplan-Meier curve of RV systolic dysfunction on the basis of RVFAC. (C)
C-statistic between RA indexes. (D) Five-year Kaplan-Meier curve and severe RA enlargement. *In A and C, the criterion value noted on the
graph is the optimal criterion value corresponding with the Youden index J with equal weight given to sensitivity and speciﬁcity. aRAEF ¼ active
right atrial emptying fractions; pRAEF ¼ passive right atrial emptying fractions; RAI ¼ right atrial area index; other abbreviations as in
Figures 1, 2, and 3.
TABLE 4 Independent Correlates of the Composite Endpoint in the Derivation Cohort
Hazard
Ratio 95% CI p Value
Overall
Chi-Square
Multivariable model—continuous
RVFAC per 5% 0.6 0.4–0.7 <0.001 44
RAI, per 5 cm2/m2 1.4 1.1–2.8 0.021 —
SBP baseline, per 10 mm Hg 0.7 0.5–0.9 0.007 —
Multivariable model—categorical
RV systolic dysfunction per grade* 3.4 2.0–7.75 <0.001 47
Severe RAE, >16 cm2/m2 3.0 1.3–8.1 0.009 —
SBP <110 mm Hg 3.3 1.5–9.4 0.002 —
RH score (categorical)
RH score, per grade 3.2 2.3–5.4 <0.001 47
*RV dysfunction was classiﬁed into normal (no dysfunction), mild, or moderate to severe according to the
American Society of Echocardiography criteria. The 95% CI are reported after 5,000 iterations of the bootstrap
procedure. Model was adjusted for age and sex.
RAE ¼ right atrial enlargement; RH ¼ right heart; other abbreviations as in Tables 1 and 2.
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635function compared with RVFAC and TAPSE in PAH;
ongoing studies are currently validating theﬁndings in
independent cohorts.
One of the most important contributions of
our study was to prove the independent contribution
to RA size (22). In fact, in contrast to studies on
atrial remodeling in left heart failure, there have
been a limited number of studies addressing at-
rial remodeling or atrial function in PAH (7,8,23).
Bustamante-Labarta et al. (7) were the ﬁrst to suggest
an association between RA size and outcome in 25
patients with PAH. In the study of Raymond et al. (8),
in 81 patients with NYHA functional class III or IV
PAH, there was a trend for an independent asso-
ciation between RA area indexed to height and
the composite endpoint of death or transplantation
(p ¼ 0.106). In the recent study of Kane et al. (23),
TABLE 5 Example of RH Score and Point Allocation
Baseline value 1 þ
RV function*
Normal 0
Mild 1
Moderate to severe 2
Less than severe RAE 0
Severe RAE 1
SBP >110 mm Hg 0
SBP <110 mm Hg 1
RH score 1 to 5
*RV dysfunction was classiﬁed into normal (no dysfunction), mild, or moderate to
severe according to the American Society of Echocardiography criteria.
Abbreviations as in Tables 1, 2, and 4.
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(A) Five-year Kaplan-Meier curve on the basis of the right heart score. (B)
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636severe RA enlargement assessed qualitatively were
also predictive of survival when corrected for age,
sex, and functional class. Mechanistically, RA size is
strongly associated with RAP, and tricuspid reg-
urgitation severity can therefore provide important
information on adverse ventricular remodeling.
However, further studies are needed to provide better
normative indexed thresholds of RA size.
In addition to changes in RA remodeling, we
showed that RA function was signiﬁcantly impaired
in patients with PAH. Although the change affected
both passive and atrial components of atrial function,
better prognostic information was provided by active
atrial emptying. The association between active RAEF
and RAP, as well as TAPSE, is not surprising because
RAP may be an indirect metric of RA afterload andres
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Imaging cardio-
vascular biomarkers have diagnostic and prognostic value and
are useful in guiding clinical management in patients with PAH.
Finding the best combination of biomarkers is essential to
translate into better diagnostic or predictive tools. In this study,
we identiﬁed right ventricular function by conventional echo-
cardiography, right atrial enlargement, and systemic systolic
blood pressure as key factors determining outcome, and a score
derived from these simple 3 parameters had prognostic power
superior to an established PAH score.
TRANSLATIONAL OUTLOOK: Additional clinical studies are
needed to validate the incremental prognostic value of simpliﬁed
imaging scores in patients with PAH.
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637TAPSE may limit the extent of active RAEF as the atria
cannot contract if the ventricle has a limited annular
excursion. As a marker of outcome, active RAEF has
the potential disadvantage of lower reproducibility
compared with maximal RA size; in addition it is more
collinearly related with metrics of RV systolic func-
tion, which may limit its incremental value in multi-
variate models. Conversely, RA size was more related
to RV end-systolic dimensions, which may limit their
incremental values if considered together as cova-
riates. The sex differences related to active RAEF
will require further study and validation. The asso-
ciation that we found between SBP and outcome was
consistent with the ﬁndings of the REVEAL registry
and may reﬂect lower cardiac output or the use of
prostanoid therapy.
Our study has 3 main clinical implications. First, a
simple right heart score can be useful for stratiﬁed
randomization strategies in phase II clinical trials
because matching based only on NYHA functional
class may not capture the complexity of the disease
process and all variables from the REVEAL registry
may not be available. Second, a simple right heart
score can serve as a “benchmark” against which
the incremental value of novel biomarkers can be
assessed. Third, empirically patients with higher
scores could be monitored more closely clinically
because they are at higher risk of clinical deteriora-
tion. However, it is important to mention that our
study was not designed to provide a comparison with
well-validated scores, such as the REVEAL registry
score, and should by no means be considered inter-
changeable. Our study does however suggest, as did
the study of Fine et al. (18), that quantitative assess-
ment of right heart function and remodeling may
simplify risk assessment in patients with PAH.
STUDY LIMITATIONS. The small sample size limited
the number of variables that we could consider in the
multivariable model. The strong relationship with the
REVEAL registry and NIH survival equation, however,
brought indirect external validation to our ﬁndings,
as did the validation cohort. Second, we did not
include more complex imaging modalities, such asstrain imaging, in our study. Finally, it is important to
emphasize that our study focused on prevalent cases
of patients with PAH, rather than incident treatment-
naive patients.
CONCLUSIONS
In this study, we showed that in patients with idio-
pathic, familial, or drug- and toxin-associated PAH,
a simple right heart score combining indexes of right
heart remodeling and function could predict long-
term outcome. If further validated, this simple score
may signiﬁcantly improve the evaluation of novel
biomarkers and help guide stratiﬁed randomization
in clinical trials.
ACKNOWLEDGMENTS The authors thank the Vera
Moulton Wall Center, Stanford Cardiovascular Insti-
tute, and Pai Chan Lee Research Fund at Stanford
University for their support.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
François Haddad, Division of Cardiovascular Medicine,
Stanford University, 300 Pasteur Drive, Palo Alto, Cali-
fornia 94305. E-mail: fhaddad@stanford.edu.RE F E RENCE S1. Humbert M, Sitbon O, Chaouat A, et al. Sur-
vival in patients with idiopathic, familial, and
anorexigen-associated pulmonary arterial hyper-
tension in the modern management era. Circula-
tion 2010;122:156–63.
2. Benza RL, Miller DP, Gomberg-Maitland M, et al.
Predicting survival in pulmonary arterial hypertension:
insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Man-
agement (REVEAL). Circulation 2010;122:164–72.
3. Vonk-Noordegraaf A, Haddad F, Chin KM, et al.
Right heart adaptation to pulmonary arterial hy-
pertension: physiology and pathobiology. J Am
Coll Cardiol 2013;62:D22–33.
4. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival
in patients with primary pulmonary hypertension.Results from a national prospective registry. Ann
Intern Med 1991;115:343–9.
5. van Wolferen SA, van de Veerdonk MC,
Mauritz GJ, et al. Clinically signiﬁcant change in
stroke volume in pulmonary hypertension. Chest
2011;139:1003–9.
6. Bossone E, D’Andrea A, D’Alto M, et al. Echo-
cardiography in pulmonary arterial hypertension:
Haddad et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 6 , 2 0 1 5
Right Heart Score in Pulmonary Hypertension J U N E 2 0 1 5 : 6 2 7 – 3 8
638from diagnosis to prognosis. J Am Soc Echo-
cardiogr 2013;26:1–14.
7. Bustamante-Labarta M, Perrone S, De La
Fuente RL, et al. Right atrial size and tricuspid
regurgitation severity predict mortality or trans-
plantation in primary pulmonary hypertension.
J Am Soc Echocardiogr 2002;15:1160–4.
8. Raymond RJ, Hinderliter AL, Willis PW, et al.
Echocardiographic predictors of adverse outcomes
in primary pulmonary hypertension. J Am Coll
Cardiol 2002;39:1214–9.
9. Simonneau G, Robbins IM, Beghetti M, et al.
Updated clinical classiﬁcation of pulmonary hy-
pertension. J Am Coll Cardiol 2009;54:S43–54.
10. Poggio ED, Wang X, Greene T, Van Lente F,
Hall PM. Performance of the modiﬁcation of diet in
renal disease and Cockcroft-Gault equations in the
estimation of GFR in health and in chronic kidney
disease. J Am Soc Nephrol 2005;16:459–66.
11. Rudski LG, Lai WW, Aﬁlalo J, et al. Guidelines
for the echocardiographic assessment of the right
heart in adults: a report from the American Society
of Echocardiography endorsed by the European
Association of Echocardiography, a registered
branch of the European Society of Cardiology, and
the Canadian Society of Echocardiography. J Am
Soc Echocardiogr 2010;23:685–713.
12. Yeo TC, Dujardin KS, Tei C, Mahoney DW,
McGoonMD, Seward JB.Valueof aDoppler-derived
index combining systolic and diastolic time in-
tervals in predicting outcome in primary pulmonary
hypertension. Am J Cardiol 1998;81:1157–61.13. Forﬁa PR, Fisher MR, Mathai SC, et al. Tricuspid
annular displacement predicts survival in pulmo-
nary hypertension. Am J Respir Crit Care Med
2006;174:1034–41.
14. van de Veerdonk MC, Kind T, Marcus JT, et al.
Progressive right ventricular dysfunction in patients
with pulmonary arterial hypertension responding to
therapy. J Am Coll Cardiol 2011;58:2511–9.
15. Shiran H, Zamanian RT, McConnell MV, et al.
Relationship between echocardiographic and
magnetic resonance derived measures of right
ventricular size and function in patients with pul-
monary hypertension. J Am Soc Echocardiogr
2014;27:405–12.
16. Laupacis A, Sekar N, Stiell IG. Clinical prediction
rules. A review and suggested modiﬁcations of
methodological standards. JAMA1997;277:488–94.
17. Thenappan T, Shah SJ, Rich S, Tian L,
Archer SL, Gomberg-Maitland M. Survival in pul-
monary arterial hypertension: a reappraisal of the
NIH risk stratiﬁcation equation. Eur Respir J 2010;
35:1079–87.
18. Fine NM, Chen L, Bastiansen PM, et al.
Outcome prediction by quantitative right ventric-
ular function assessment in 575 subjects evaluated
for pulmonary hypertension. Circ Cardiovasc Im-
aging 2013;6:711–21.
19. Shiran H, Haddad F, Miller DC, Liang D. Com-
parison of aortic root diameter to left ventricular
outﬂow diameter versus body surface area in pa-
tients with Marfan syndrome. Am J Cardiol 2012;
110:1518–22.20. Kind T, Mauritz GJ, Marcus JT, van de
Veerdonk M, Westerhof N, Vonk-Noordegraaf A.
Right ventricular ejection fraction is better re-
ﬂected by transverse rather than longitudinal wall
motion in pulmonary hypertension. J Cardiovasc
Magn Reson 2010;12:35.
21. Ghio S, Klersy C, Magrini G, et al. Prognostic
relevance of the echocardiographic assessment of
right ventricular function in patients with idio-
pathic pulmonary arterial hypertension. Int J Car-
diol 2010;140:272–8.
22. Grunig E, Henn P, D’Andrea A, et al. Refer-
ence values for and determinants of right atrial
area in healthy adults by 2-dimensional echo-
cardiography. Circ Cardiovasc Imaging 2013;6:
117–24.
23. Kane GC, Maradit-Kremers H, Slusser JP,
Scott CG, Frantz RP, McGoon MD. Integration of
clinical and hemodynamic parameters in the pre-
diction of long-term survival in patients with
pulmonary arterial hypertension. Chest 2011;139:
1285–93.
KEY WORDS atrial function, heart failure,
outcome, pulmonary hypertension, right
heart
Go to http://cme.jaccjournals.org
to take the CME quiz for this
article.
